521MO Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial (2022)
Attributed to:
Immunotherapy and clear cell ovarian cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.annonc.2022.07.649
Publication URI: http://dx.doi.org/10.1016/j.annonc.2022.07.649
Type: Journal Article/Review
Parent Publication: Annals of Oncology